China-based Triastek has entered into a collaboration and license agreement with Johnson & Johnson to develop oral medicines using its pharmaceutical 3D printing and drug delivery technologies. J&J will also make an equity investment through its venture capital arm, Johnson & Johnson Innovation–JJDC. Financial terms were not disclosed.
The collaboration will apply Triastek’s technology to oral delivery of peptides and other therapeutic modalities. The announcement did not identify specific drug candidates or indications, or disclose development timelines.
Triastek’s Melt Extrusion Deposition plus Semi-Solid Extrusion (MED&SSE) process combines tablet manufacturing with control over internal structure and drug release. Its 3D Microstructure for Oral Macromolecules (3DμS-OM) platform is designed to address oral delivery challenges, including protecting peptides from degradation and delivering them to the intended absorption site. Triastek says its low-temperature manufacturing approach helps preserve sensitive active ingredients.
The technology also underpins Triastek’s T25, an investigational oral octreotide acetate tablet for maintenance treatment of adults with acromegaly who have responded to and tolerated somatostatin analogs. T25 received US FDA clearance for clinical testing in April 2026, followed by Chinese clearance in July. The J&J announcement did not identify T25 as part of the collaboration.